Mendelian randomization in nutritional epidemiology

Nutrition Reviews

Volumn 67, Issue 8, 2009, Pages 439-450

  Qi, Lu ^a,b,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CHANNING LABORATORY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Mendelian randomization; Nutritional epidemiology; Review

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALDEHYDE DEHYDROGENASE ISOENZYME 2; C REACTIVE PROTEIN; FIBRINOGEN; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HEMOGLOBIN A1C; HOMOCYSTEINE; INTERLEUKIN 18; INTERLEUKIN 6; LACTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ALCOHOL CONSUMPTION; ALLELE; DAIRY PRODUCT; DIET; ENVIRONMENTAL EXPOSURE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIFESTYLE; MENDELIAN RANDOMIZATION; NUTRITION; OBESITY; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; UTERUS; VEGETABLE;

ALCOHOL DRINKING; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIET; EPIDEMIOLOGY; FEMALE; GENETIC VARIATION; HEREDITY; HUMANS; LIFE STYLE; NEOPLASMS; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; OBESITY; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77956018249     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2009.00218.x     Document Type: Review

References (65)

1. Willett W. Nutritional Epidemiology. New York Oxford: Oxford University Press; 1998.
2. Willett WC, Stampfer MJ,Manson JE, et al. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet. 1993;341:581-585.
3. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783-1789.
4. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679. (Pubitemid 46048554)
5. Smith GD, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. PLoS Med. 2007;4:e352.
6. Phillips A. Commentary: balancing quantity and quality when designing epidemiological studies. Int J Epidemiol. 2003;32:58-59.
7. Davey Smith G, Ebrahim S. What can Mendelian randomisation tell us about modifiable behavioural and environmental exposures?. BMJ. 2005;330:1076-1079.
8. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res. 2007;16:309-330.
9. Morgan TH. Physical Basis of Heredity. Philadelphia: JB Lipincott Company; 1919.
10. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet. 1986;1:507-508.
11. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630.
12. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33:30-42.
13. Nitsch D, Molokhia M, Smeeth L, DeStavola BL, Whittaker JC, Leon DA. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol. 2006;163:397-403.
14. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133-1163.
15. Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet. 2005;366:1954-1959.
16. KivimakiM, Lawlor DA, Eklund C, et al.Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study. Arterioscler Thromb Vasc Biol. 2007;27:978-979.
17. Kivimaki M, Davey Smith G, Timpson NJ, et al. Lifetime body mass index and later atherosclerosis risk in young adults: examining causal links using Mendelian randomization in the Cardiovascular Risk in Young Finns study. Eur Heart J. 2008;25:2552-2560.
18. Minelli C, Thompson JR, Tobin MD, Abrams KR. An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. Am J Epidemiol. 2004; 160:445-452.
19. Chen L, Davey Smith G, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med. 2008;5:e52.
20. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol. 2000;29:1102.
21. Staiger D, Stock JH. Instrumental variables with weak instruments. Econometrica. 1997;65:557-586.
22. Linsel-Nitschke P, Gotz A, Erdmann J, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease - a Mendelian randomisation study. PLoS ONE. 2008;3:e2986.
23. Morita M, Saeki H, Mori M, Kuwano H, Sugimachi K. Risk factors for esophageal cancer and the multiple occurrence of carcinoma in the upper aerodigestive tract. Surgery. 2002;131 (Suppl):S1-S6.
24. Blot WJ. Alcohol and cancer. Cancer Res. 1992; 52(Suppl):S2119-S2123.
25. Lewis SJ, Smith GD. Alcohol, ALDH2, and esophageal cancer: a meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiol Biomarkers Prev. 2005;14:1967-1971.
26. Enomoto N, Takase S, Yasuhara M, Takada A. Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes. Alcohol Clin Exp Res. 1991;15:141-144.
27. Gutjahr E, Gmel G, Rehm J. Relation between average alcohol consumption and disease: an overview. Eur Addict Res. 2001;7:117-127.
28. Yokoyama A, Kato H, Yokoyama T, et al. Genetic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, smoking, and diet in Japanese men with esophageal squamous cell carcinoma. Carcinogenesis. 2002;23:1851-1859.
29. Sacerdote C, Guarrera S, Smith GD, et al. Lactase persistence and bitter taste response: instrumental variables and Mendelian randomization in epidemiologic studies of dietary factors and cancer risk. Am J Epidemiol. 2007;166:576-581.
30. Grand RJ, Montgomery RK, Chitkara DK, Hirschhorn JN. Changing genes; losing lactase. Gut. 2003;52:617-619.
31. Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I. Identification of a variant associatedwith adult-type hypolactasia. Nat Genet. 2002;30:233-237.
32. Kim UK, Jorgenson E, Coon H, Leppert M, Risch N, Drayna D. Positional cloning of the human quantitative trait locus underlying taste sensitivity to phenylthiocarbamide. Science. 2003;299:1221-1225.
33. Weiss KM. The unkindest cup. Lancet. 2004;363:1489-1490.
34. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889-894.
35. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107-2116.
36. Qi L, Doria A, Manson JE, et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. Diabetes. 2006;55:1512-1516.
37. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843. (Pubitemid 30165206)
38. Qi L, Meigs JB, Liu S, Manson JE, Mantzoros C, Hu FB. Dietary fibers and glycemic load, obesity, and plasma adiponectin levels in women with type 2 diabetes. Diabetes Care. 2006;29:1501-1505.
39. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rimm EB. Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers. Obes Res. 2003; 11:1055-1064.
40. Frayling TM, Rafiq S, Murray A, et al. An interleukin-18 polymorphism is associated with reduced serum concentrations and better physical functioning in older people. J Gerontol A Biol Sci Med Sci. 2007;62:73-78.
41. Qi L, Rifai N, Hu FB. Interleukin-6 receptor gene variations, plasma interleukin-6 levels, and type 2 diabetes in U.S. women. Diabetes. 2007;56:3075-3081.
42. Keavney B, Danesh J, Parish S, et al. Fibrinogen and coronary heart disease: test of causality by"Mendelian randomization." Int J Epidemiol. 2006;35:935-943.
43. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from Mendelian randomisation. Lancet. 2005;365:224-232.
44. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951.
45. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391-397.
46. de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta. 2002;317:1-15.
47. Davey Smith G, Lawlor DA, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005;25:1051-1056.
48. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002;162:217-219.
49. Casas JP, Shah T, Cooper J, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 2006;35:922-931.
50. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
51. Kivimaki M, Lawlor DA, Smith GD, et al. Does high C-reactive protein concentration increase atherosclerosis? TheWhitehall II Study. PLoS ONE. 2008;3:e3013.
52. Brunner EJ, Kivimaki M, Witte DR, et al. Inflammation, insulin resistance, and diabetes - Mendelian randomization using CRP haplotypes points upstream. PLoS Med. 2008; 5:e155.
53. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA. 2005;294:1799-1809.
54. Bailey LB, Gregory JF, 3rd. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr. 1999;129:919-922.
55. Reich D, Patterson N, Ramesh V, et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels. Am J Hum Genet. 2007;80:716-726.
56. Smith GD. Assessing intrauterine influences on offspring health outcomes: can epidemiological studies yield robust findings?. Basic Clin Pharmacol Toxicol. 2008;102:245-256.
57. Barker DJ. Adult consequences of fetal growth restriction. Clin Obstet Gynecol. 2006;49:270-283.
58. Phillips DI, Jones A, Goulden PA. Birth weight, stress, and the metabolic syndrome in adult life. Ann N Y Acad Sci. 2006;1083:28-36.
59. Martins IJ, Hone E, Foster JK, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry. 2006;11:721-736.
60. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487-495.
61. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet. 2003;361:598-604.
62. Bochud M, Chiolero A, Elston RC, Paccaud F. A cautionary note on the use of Mendelian randomization to infer causation in observational epidemiology. Int J Epidemiol. 2008;37:414-416; author reply 416-417.
63. Temple IK. Imprinting in human disease with special reference to transient neonatal diabetes and Beckwith- Wiedemann syndrome. Endocr Dev. 2007;12:113-123.
64. Loos RJ, Lindgren CM, Li S, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet. 2008;40:768-775.
65. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633-637.